Lantern Pharma Inc (LTRN)

$3.59 +0.09 (2.57%)
Market Cap 40.59M
Revenue (ttm) 0.00
Net Income (ttm) -17.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 116,500
Avg Vol 816,096
Day's Range N/A - N/A
Shares Out 11.31M
Stochastic %K 84%
Beta 2.10
Analysts Strong Sell
Price Target $25.00

Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central ner...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 277 1136
Address:
1920 McKinney Avenue, 7th Floor, Dallas, United States
real_elonmusk
real_elonmusk May. 28 at 5:11 PM
$LTRN 🔥🔥🔥🔥🚀🚀🚀🚀 SUPER
0 · Reply
VolcanicTrades
VolcanicTrades May. 28 at 4:52 PM
$LTRN
0 · Reply
real_elonmusk
real_elonmusk May. 26 at 8:21 PM
$LTRN picked up bunch today 🔥🔥🔥🔥🚀🚀🚀🚀🚀
0 · Reply
VolcanicTrades
VolcanicTrades May. 26 at 2:17 PM
$LTRN $5-$11 👀📈
0 · Reply
Rmccall
Rmccall May. 26 at 4:11 AM
$LTRN just got into this one. Any legs??? Thanks
0 · Reply
VolcanicTrades
VolcanicTrades May. 22 at 9:43 PM
$LTRN
0 · Reply
STACKD0E
STACKD0E May. 22 at 9:36 PM
$QTEX $LTRN
0 · Reply
Djohn75
Djohn75 May. 22 at 1:11 PM
$LTRN Is there any thought to the idea that LTRN may develop in to a takeover target from one of the big Pharma companies?
2 · Reply
mankind1
mankind1 May. 20 at 5:37 PM
$LTRN nothing but consistently good news coming out of this one. The market will catch-up. Right now, it is focused on Space (for good reason), but it'll eventually see LTRN.
0 · Reply
real_elonmusk
real_elonmusk May. 20 at 2:28 PM
$LTRN 🔥🔥🔥🔥🔥🚀🚀🚀🚀🚀 SUPER
0 · Reply
Latest News on LTRN
Lantern receives successful response to Type C meeting from FDA on LP-300

2026-05-19T11:41:54.000Z - 13 days ago

Lantern receives successful response to Type C meeting from FDA on LP-300

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

May 19, 2026, 7:30 AM EDT - 13 days ago

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026, 4:01 PM EDT - 16 days ago

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

Lantern Pharma Earnings release: Q1 2026

May 15, 2026, 4:00 PM EDT - 16 days ago

Lantern Pharma Earnings release: Q1 2026

Lantern Pharma Quarterly report: Q1 2026

May 15, 2026, 4:00 PM EDT - 16 days ago

Lantern Pharma Quarterly report: Q1 2026

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 14, 2026, 4:05 PM EDT - 17 days ago

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

Lantern Pharma prices 2.14M shares at $2.06 in registered direct offering

2026-05-13T16:45:38.000Z - 18 days ago

Lantern Pharma prices 2.14M shares at $2.06 in registered direct offering

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 13, 2026, 8:00 AM EDT - 19 days ago

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

May 11, 2026, 4:30 PM EDT - 20 days ago

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

Lantern Pharma unveils roadmap for withZeta.ai

2026-05-07T19:23:32.000Z - 24 days ago

Lantern Pharma unveils roadmap for withZeta.ai

Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

May 7, 2026, 9:01 AM EDT - 25 days ago

Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

Lantern Pharma Transcript: Investor update

Apr 30, 2026, 8:30 AM EDT - 4 weeks ago

Lantern Pharma Transcript: Investor update

Lantern Pharma announces expansion of predictBBB.ai into LQM

2026-04-29T13:54:13.000Z - 4 weeks ago

Lantern Pharma announces expansion of predictBBB.ai into LQM

Lantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

Apr 29, 2026, 8:50 AM EDT - 4 weeks ago

Lantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

Lantern Pharma announces public demonstration of withZeta.ai

2026-04-24T11:56:40.000Z - 5 weeks ago

Lantern Pharma announces public demonstration of withZeta.ai

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

Apr 24, 2026, 7:50 AM EDT - 5 weeks ago

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

Lantern Pharma schedules Type C meeting with FDA for Phase 2 HARMONIC trial

2026-04-20T13:18:19.000Z - 6 weeks ago

Lantern Pharma schedules Type C meeting with FDA for Phase 2 HARMONIC trial

Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

Apr 20, 2026, 8:05 AM EDT - 6 weeks ago

Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

Lantern Pharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 2:30 PM EDT - 6 weeks ago

Lantern Pharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Lantern Pharma launches withZeta.ai

2026-04-14T12:46:58.000Z - 6 weeks ago

Lantern Pharma launches withZeta.ai

Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Apr 14, 2026, 8:31 AM EDT - 6 weeks ago

Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Lantern Pharma to host live demonstration of withZeta.ai

2026-04-02T12:15:05.000Z - 2 months ago

Lantern Pharma to host live demonstration of withZeta.ai

Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

Apr 2, 2026, 8:10 AM EDT - 2 months ago

Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

Lantern Pharma Earnings Call Transcript: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 2 months ago

Lantern Pharma Earnings Call Transcript: Q4 2025

Lantern Pharma Annual report: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 2 months ago

Lantern Pharma Annual report: Q4 2025

Lantern Pharma Earnings release: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 2 months ago

Lantern Pharma Earnings release: Q4 2025

Lantern Pharma Slides: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 2 months ago

Lantern Pharma Slides: Q4 2025

Lantern Pharma reports Q4 net income ($4.1M) vs ($5.9M) last year

2026-03-30T20:22:13.000Z - 2 months ago

Lantern Pharma reports Q4 net income ($4.1M) vs ($5.9M) last year

Lantern Pharma says article on CEO leaving ‘false and misleading’

2026-03-30T20:21:32.000Z - 2 months ago

Lantern Pharma says article on CEO leaving ‘false and misleading’

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 30, 2026, 4:05 PM EDT - 2 months ago

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Lantern Pharma Slides: Corporate presentation

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Lantern Pharma Slides: Corporate presentation

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Mar 27, 2026, 7:23 PM EDT - 2 months ago

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Lantern, Starlight announces FDA clearance of IND for Phase 1 trial of STAR-001

2026-03-27T11:38:18.000Z - 2 months ago

Lantern, Starlight announces FDA clearance of IND for Phase 1 trial of STAR-001

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Mar 27, 2026, 7:29 AM EDT - 2 months ago

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Mar 23, 2026, 4:30 PM EDT - 2 months ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Lantern Pharma Transcript: AI Investor Conference: From Data Centers to Breakthrough Use Cases

Mar 19, 2026, 11:00 AM EDT - 2 months ago

Lantern Pharma Transcript: AI Investor Conference: From Data Centers to Breakthrough Use Cases

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

Feb 10, 2026, 8:45 AM EST - 3 months ago

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

Lantern Pharma gets orphan drug designation for LP-284 from FDA

2026-01-20T13:16:59.000Z - 4 months ago

Lantern Pharma gets orphan drug designation for LP-284 from FDA

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Jan 20, 2026, 8:00 AM EST - 4 months ago

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Lantern Pharma’s treatment of soft tissue sarcoma granted orphan designation

2026-01-16T02:40:07.000Z - 4 months ago

Lantern Pharma’s treatment of soft tissue sarcoma granted orphan designation

Lantern Pharma establishes India AI center to industrialize RADR platform

2026-01-12T14:32:18.000Z - 5 months ago

Lantern Pharma establishes India AI center to industrialize RADR platform

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies

Jan 12, 2026, 9:00 AM EST - 5 months ago

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies

Lantern Pharma Slides: corporate presentation

Jan 8, 2026, 7:00 AM EST - 5 months ago

Lantern Pharma Slides: corporate presentation

Lantern Pharma announces LP-184 clinical trial met all primary endpoints

2025-12-03T13:55:54.000Z - 6 months ago

Lantern Pharma announces LP-184 clinical trial met all primary endpoints

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

Dec 3, 2025, 8:35 AM EST - 6 months ago

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

Lantern Pharma Transcript: Status Update

Nov 20, 2025, 4:30 PM EST - 6 months ago

Lantern Pharma Transcript: Status Update

Lantern Pharma Earnings Call Transcript: Q3 2025

Nov 13, 2025, 9:00 AM EST - 7 months ago

Lantern Pharma Earnings Call Transcript: Q3 2025

Lantern Pharma Earnings release: Q3 2025

Nov 13, 2025, 9:00 AM EST - 7 months ago

Lantern Pharma Earnings release: Q3 2025

Lantern Pharma Quarterly report: Q3 2025

Nov 13, 2025, 9:00 AM EST - 7 months ago

Lantern Pharma Quarterly report: Q3 2025

Lantern Pharma Slides: Q3 2025

Nov 13, 2025, 9:00 AM EST - 7 months ago

Lantern Pharma Slides: Q3 2025

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 13, 2025, 8:30 AM EST - 7 months ago

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Lantern Pharma management to meet virtually with Lake Street

2025-11-12T15:25:42.000Z - 7 months ago

Lantern Pharma management to meet virtually with Lake Street

Lantern Pharma engages New to The Street for media program

2025-11-07T14:10:19.000Z - 7 months ago

Lantern Pharma engages New to The Street for media program

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Nov 6, 2025, 8:00 AM EST - 7 months ago

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Lantern Pharma Transcript: 2025 ThinkEquity Conference

Oct 30, 2025, 11:30 AM EDT - 7 months ago

Lantern Pharma Transcript: 2025 ThinkEquity Conference

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Oct 28, 2025, 8:49 AM EDT - 7 months ago

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

Oct 24, 2025, 8:00 AM EDT - 7 months ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

Sep 16, 2025, 8:29 AM EDT - 9 months ago

Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

Sep 10, 2025, 8:00 AM EDT - 9 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Sep 3, 2025, 9:44 AM EDT - 9 months ago

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Lantern Pharma Transcript: Investor Update

Aug 26, 2025, 4:15 PM EDT - 9 months ago

Lantern Pharma Transcript: Investor Update

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Aug 13, 2025, 4:30 PM EDT - 10 months ago

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Lantern Pharma Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 10 months ago

Lantern Pharma Earnings release: Q2 2025

Lantern Pharma Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 10 months ago

Lantern Pharma Quarterly report: Q2 2025

Lantern Pharma Proxy statement: Proxy Filing

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Lantern Pharma Proxy statement: Proxy Filing

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Aug 6, 2025, 8:30 AM EDT - 10 months ago

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Aug 4, 2025, 8:55 AM EDT - 10 months ago

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Lantern Pharma Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Lantern Pharma Proxy statement: Proxy Filing

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Jul 23, 2025, 7:56 AM EDT - 11 months ago

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Jul 21, 2025, 8:20 AM EDT - 11 months ago

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Jul 15, 2025, 9:40 AM EDT - 11 months ago

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Jun 16, 2025, 8:30 AM EDT - 1 year ago

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

May 29, 2025, 8:30 AM EDT - 1 year ago

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

Lantern Pharma Earnings Call Transcript: Q1 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Lantern Pharma Earnings Call Transcript: Q1 2025

Lantern Pharma Quarterly report: Q1 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Lantern Pharma Quarterly report: Q1 2025

Lantern Pharma Earnings release: Q1 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Lantern Pharma Earnings release: Q1 2025

Lantern Pharma Slides: Q1 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Lantern Pharma Slides: Q1 2025

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

May 15, 2025, 8:45 AM EDT - 1 year ago

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

May 12, 2025, 9:00 AM EDT - 1 year ago

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

May 8, 2025, 8:30 AM EDT - 1 year ago

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

May 5, 2025, 8:55 AM EDT - 1 year ago

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Lantern Pharma Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Lantern Pharma Earnings Call Transcript: Q4 2024

Lantern Pharma Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Lantern Pharma Annual report: Q4 2024

Lantern Pharma Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Lantern Pharma Earnings release: Q4 2024

Lantern Pharma Slides: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Lantern Pharma Slides: Q4 2024

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Feb 19, 2025, 8:00 AM EST - 1 year ago

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Jan 27, 2025, 7:55 AM EST - 1 year ago

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Dec 9, 2024, 8:15 AM EST - 1 year ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Dec 3, 2024, 8:00 AM EST - 1 year ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 26, 2024, 8:45 AM EST - 1 year ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Nov 19, 2024, 8:00 AM EST - 1 year ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Lantern Pharma Earnings Call Transcript: Q3 2024

Lantern Pharma Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Lantern Pharma Quarterly report: Q3 2024

Lantern Pharma Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Lantern Pharma Earnings release: Q3 2024

Lantern Pharma Slides: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Lantern Pharma Slides: Q3 2024

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

real_elonmusk
real_elonmusk May. 28 at 5:11 PM
$LTRN 🔥🔥🔥🔥🚀🚀🚀🚀 SUPER
0 · Reply
VolcanicTrades
VolcanicTrades May. 28 at 4:52 PM
$LTRN
0 · Reply
real_elonmusk
real_elonmusk May. 26 at 8:21 PM
$LTRN picked up bunch today 🔥🔥🔥🔥🚀🚀🚀🚀🚀
0 · Reply
VolcanicTrades
VolcanicTrades May. 26 at 2:17 PM
$LTRN $5-$11 👀📈
0 · Reply
Rmccall
Rmccall May. 26 at 4:11 AM
$LTRN just got into this one. Any legs??? Thanks
0 · Reply
VolcanicTrades
VolcanicTrades May. 22 at 9:43 PM
$LTRN
0 · Reply
STACKD0E
STACKD0E May. 22 at 9:36 PM
$QTEX $LTRN
0 · Reply
Djohn75
Djohn75 May. 22 at 1:11 PM
$LTRN Is there any thought to the idea that LTRN may develop in to a takeover target from one of the big Pharma companies?
2 · Reply
mankind1
mankind1 May. 20 at 5:37 PM
$LTRN nothing but consistently good news coming out of this one. The market will catch-up. Right now, it is focused on Space (for good reason), but it'll eventually see LTRN.
0 · Reply
real_elonmusk
real_elonmusk May. 20 at 2:28 PM
$LTRN 🔥🔥🔥🔥🔥🚀🚀🚀🚀🚀 SUPER
0 · Reply
mankind1
mankind1 May. 20 at 6:33 AM
$LTRN this wants to go big. Can you feel it?
0 · Reply
Bulltrader988
Bulltrader988 May. 19 at 9:05 PM
$LTRN Oh nice 13D/A filled on 2026-05-15: Bios Equity Partners increased their position again... From 420,802 shares (3.7 % ownership) to 571,305 shares (4.48 % ownership) 👃👀 https://www.sec.gov/Archives/edgar/data/1763950/000181331426000008/xslSCHEDULE_13D_X02/primary_doc.xml
0 · Reply
Bulltrader988
Bulltrader988 May. 19 at 2:39 PM
$LTRN 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-announces-successful-outcome-of-fda-type-c-meeting-vlgvzj2uw4jm.html
0 · Reply
VolcanicTrades
VolcanicTrades May. 19 at 12:05 PM
$LTRN the lantern has news 👀
0 · Reply
DARKP00L
DARKP00L May. 19 at 11:59 AM
$LTRN 07:37 on May. 19 2026 Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer Adenocarcinoma #tradeideas
0 · Reply
DARKP00L
DARKP00L May. 19 at 11:57 AM
$LTRN 07:37 on May. 19 2026 Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer Adenocarcinoma #tradeideas
0 · Reply
mankind1
mankind1 May. 18 at 10:13 PM
$LTRN this is in a great position.
0 · Reply
Bulltrader988
Bulltrader988 May. 16 at 4:21 PM
$LTRN And another Form 4: Another Director bought 48,544 shares from offering at $2.06 on 05/12/2026 👃👀 https://www.sec.gov/Archives/edgar/data/1393516/000149315226023082/xslF345X06/ownership.xml
0 · Reply
Bulltrader988
Bulltrader988 May. 16 at 4:18 PM
$LTRN Form 4 : Director bought 48,544 shares from offering at $2.06 on 05/12/2026 👃👀 https://www.sec.gov/Archives/edgar/data/1763950/000149315226023083/xslF345X06/ownership.xml
0 · Reply
pochiwonka
pochiwonka May. 16 at 12:05 PM
$LTRN wth this company has no revneue...
0 · Reply
MaxPain_Trader
MaxPain_Trader May. 15 at 11:31 PM
$LTRN doubled down
0 · Reply
Lussu1986
Lussu1986 May. 15 at 6:47 PM
$LTRN Looks like the raised just enough cash to pay the CEO and rest of management a little longer before driving into the ditch for good.
1 · Reply